Prognostic significance of unexplained elevated amniotic fluid alpha-fetoprotein

Obstetrics and Gynecology

Volumn 87, Issue 2, 1996, Pages 213-216

  Wenstrom, Katharine D ^a   Owen, John ^a   Davis, Richard O ^a   Brumfield, Cynthia G ^a  

^a Division of Maternal Fetal Medicine   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA FETOPROTEIN;

AMNION FLUID ANALYSIS; ARTICLE; DIAGNOSIS; EPIDEMIOLOGY; FEMALE; FETUS GROWTH; FETUS MALFORMATION; HUMAN; HUMAN CELL; HUMAN TISSUE; MAJOR CLINICAL STUDY; MATERNAL BLOOD; NEWBORN; PREDICTION; PREECLAMPSIA; PREGNANCY COMPLICATION; PRIORITY JOURNAL; PROGNOSIS; STILLBIRTH;

ALPHA-FETOPROTEINS; AMNIOTIC FLUID; FEMALE; HUMANS; INCIDENCE; PREGNANCY; PREGNANCY COMPLICATIONS; PREGNANCY OUTCOME; PROGNOSIS;

EID: 85029981276     PISSN: 00297844     EISSN: 1873233X     Source Type: Journal    
DOI: 10.1080/00006250-199602000-00011     Document Type: Article

References (15)

1. Burton BK, Sowers SG, Nelson LH. Maternal serum a-fetoprotein screening in North Carolina: Experience with more than twelve thousand pregnancies. Am J Obstet Gynecol 1983;146:439-44.
2. Haddow JE, Kloza EM, Smith DE, Knight GJ. Data from an alpha-fetoprotein pilot screening program in Maine. Obstet Gynecol 1983;62:556-60.
3. Adams MJ, Windham GC, James LM, et al. Clinical interpretation of maternal serum a-fetoprotein concentrations. Am J Obstet Gynecol 1984;148:241-54.
4. Burton BK. Elevated maternal serum alpha-fetoprotein (MSAFP): Interpretation and follow-up. Clin Obstet Gynecol 1988;31:293-305.
5. Crandall BF, Matsumoto M. Risks associated with an elevated amniotic fluid a-fetoprotein level. Am J Med Genet 1991;39:64-7.
6. Brenner WE, Edelman DA, Hendricks CH. A standard of fetal growth for the United States of America. AmJ Obstet Gynecol 1976;126:555-61.
7. Waller DK, Lustig LS, Cunningham GC, Golbus MS, Hook EB. Second trimester maternal serum alpha-fetoprotein levels and the risk of subsequent fetal death. N Engl J Med 1991;325:6-10.
8. Williams MA, Hickok DE, Zingheim RW, et al. Elevated maternal serum a-fetoprotein levels and midtrimester placental abnormalities in relation to subsequent adverse pregnancy outcomes. Am J Obstet Gynecol 1992;167:1032-7.
9. Wenstrom KD, Sipes SL, Williamson RA, Grant SS, Trawick DC, Estle LC. Prediction of pregnancy outcome with single versus serial maternal serum a-fetoprotein tests. Am J Obstet Gynecol 1992;167:1529-33.
10. Benacerraf BR, Frigoletto FD. Amniocentesis under continuous ultrasound guidance: A series of 232 cases. Obstet Gynecol 1983; 62:760-3.
11. Milunsky A. Prenatal diagnosis of neural tube and other congenital defects. In: Milunsky A, ed. Genetic disorders and the fetus. 2nd ed. New York: Plenum Press, 1986:469-74.
12. Zeltzer PM, Neerhont RC, Fonkalsrud EW, Stiehm ER. Differentiation between neonatal hepatitis and biliary atresia by measuring serum alpha-fetoprotein. Lancet 1974;1:373-5.
13. Katz VL, Cefalo RC, McCune BK, Moos MK. Elevated second trimester maternal serum alpha-fetoprotein and cytomegalovirus infection. Obstet Gynecol 1986;68:580-1.
14. Cox WL, Daffos F, Forestier F, et al. Physiology and management of intrauterine growth retardation: A biologic approach with fetal blood sampling. Am J Obstet Gynecol 1988;159:36-41.
15. Caballero C, Vekemaus M, Lopez del Campo JG, Robyn C. Serum alpha-fetoprotein in adults, in women during pregnancy, in children at birth, and during the first week of life: A sex difference. Am J Obstet Gynecol 1977;127:384-9.